Patent ID: 11913959
Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
Field: Pharmaceuticals (Chemistry)
Classification: CPC G  A  C | IPC A  C  G

Claim 0:
1. A method of treating mutant tumor-infiltrating leukocytes comprising:
determining that a patient having a nonhematopoietic malignant tumor comprising a breast tumor has one or more somatic gene mutations present in tumor-infiltrating leukocytes of the breast tumor, wherein the one or more somatic gene mutations are present in one or more genes selected from the group consisting of KDM5C, CDK8, MPL, ARID1A, FLT3, FGFR1, JAK1, GLI1, EZH2, EP300, BCOR, NF1, SMARCB1, EPHA10, IRF4, INSR, EPHA2, SMO, DUSP27, NOTCH2, HNF1A, MYO18A, MET, RPTOR, ATP10A, PTCH1, BRCA1, NCOR2, PASD1, NEB, MUC4, POU2F2, HLA-A, ALK, TET2, HLA-B, FGFR4, GATA2, FLT1, ATM, ITK, FREM2, INPP4B, CSF1R, PIGN, SOX17, MLL4, TTC28, TNFSF9, TRRAP, DNMT3A, TP53, IDH2, EPHA7, WT1, PNRC1, EGFR, ETV6, SMARCA4, MLL2, MAP3K1, ALOX12B, ARID2, EPHA8, ERBB2, EPHA4, PBRM1, BCL6, HDAC2, EPHA7, MEL, CYLD, CEBPA, JAK3, ASXL1, KIT, MEF2B, and ERG; are in a coding region, and result in an amino acid substitution or a premature stop codon; and are not identified in neoplastic cells of the breast tumor itself; and
administering to the patient determined to have the one or more somatic gene mutations present in the tumor-infiltrating leukocytes of the breast tumor an agent that preferentially kills or inhibits proliferation or activity of leukocytes relative to nonhematopoietic cells, wherein the agent is known or indicated to treat leukemia and comprises a leukocyte-specific antibody.